Intensity Therapeutics(US:INTS) Ge Long Hui A P P·2025-10-31 09:08Core Insights - Intensity Therapeutics (INTS.US) experienced a pre-market drop of 37.88% to $0.82 after a significant increase of 394.57% the previous day, recovering losses from over six months [1] - The company announced results from its Phase 1/2 clinical trial for its cancer candidate INT230-6, showing an increase in activated CD4+ and CD8+ T cells in the tumor microenvironment [1] - The trial involved 64 patients across more than 20 cancer types, all of whom had undergone extensive prior treatments, achieving a disease control rate of 75% [1] Company Performance - The closing price on October 30 was $1.32, with a significant trading volume of 1.434 billion shares [1] - The stock reached a high of $1.74 and a low of $0.64 during the trading session, with a previous close of $0.267 [1] - The market capitalization stood at approximately $64.75 million, with a total share count of about 49.06 million [1] Clinical Trial Results - The clinical trial results indicated a promising potential for a new cancer treatment method, resonating positively with the market [1] - CEO Lewis Bender highlighted the early data's significance in the field of solid tumor treatment, expressing hope for broader patient benefits [1]